Dr. Sandeep Vaid
Claim this profileVista Clinical Research
Studies Arthritis
Studies Rheumatoid Arthritis
9 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Sandeep Vaid is currently running
Pegloticase + Methotrexate
for Gout
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Recruiting3 awards Phase 4
Wireless Neuromodulation
for Chronic Knee Pain
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Recruiting0 awards N/A6 criteria
More about Sandeep Vaid
Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sandeep Vaid has experience with
- GSK3196165 (Otilimab)
- Tofacitinib
- Placebo To GSK3196165 (Otilimab)
- Placebo To Tofacitinib
- CsDMARDs
- Galcanezumab
Breakdown of trials Sandeep Vaid has run
Arthritis
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Rheumatoid Arthritis
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Lower Back Pain
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sandeep Vaid specialize in?
Sandeep Vaid focuses on Arthritis and Rheumatoid Arthritis. In particular, much of their work with Arthritis has involved treating patients, or patients who are undergoing treatment.
Is Sandeep Vaid currently recruiting for clinical trials?
Yes, Sandeep Vaid is currently recruiting for 2 clinical trials in Newnan Georgia. If you're interested in participating, you should apply.
Are there any treatments that Sandeep Vaid has studied deeply?
Yes, Sandeep Vaid has studied treatments such as GSK3196165 (Otilimab), Tofacitinib, Placebo to GSK3196165 (Otilimab).
What is the best way to schedule an appointment with Sandeep Vaid?
Apply for one of the trials that Sandeep Vaid is conducting.
What is the office address of Sandeep Vaid?
The office of Sandeep Vaid is located at: Vista Clinical Research, Newnan, Georgia 30265 United States. This is the address for their practice at the Vista Clinical Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.